Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Chiara
Contact Chiara, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors - Nature Communications
Abstract Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1) R132C and R132H variants, is approved for the treatment of acute myeloid leukaemia (AML). Resistance to ivosidenib due to a second site mutation of IDH1 R132C, leading to IDH1 R132C/S280F, has emerged.
Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis
Enhanced Proline Synthesis in IDH1-Mutated Cells Is Mediated through PYCR1 Increased PYCR1 Expression and Proline Synthesis Is Observed in IDH1-Mutated Gliomas We therefore examined whether IDH1 mutant cells demonstrated altered proline biosynthetic enzyme expression. Proline is synthesized from glutamate in two steps; pyrroline 5-carboxylate (P5C) synthase (encoded by ALDH18A1) followed by either of two P5C reductases (PYCR1 and PYCR2; Figure 1Figure 1E).
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Chiara
Contact Chiara, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack